Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin(Icahn School of Medicine at Mount Sinai), Ludwig Kappos(University Hospital of Basel), Fonda Liu(Novartis (United States)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Catherine Lubetzki(Centre National de la Recherche Scientifique), Hans‐Peter Hartung(The University of Sydney), Howard L. Weiner(Baylor College of Medicine), Dieter A. Häring(Novartis (Switzerland)), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Norman Putzki(Novartis (Switzerland)), Bingbing Li(Novartis (France)), David H. Miller(National Hospital for Neurology and Neurosurgery), Mark S. Freedman, Bernard M.J. Uitdehaag(Amsterdam Neuroscience), Martin Merschhemke(Novartis (Switzerland)), Bruce Cree(University of California, San Francisco)
Cited by 449
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k